Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2026-01-14 | 2026-01-14 |
| Drug Identification Number | 02139502 | 02139502 |
| Brand name | VASOPRESSIN INJECTION, USP | VASOPRESSIN INJECTION, USP |
| Common or Proper name | VASOPRESSIN INJECTION, USP | VASOPRESSIN INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | VASOPRESSIN | VASOPRESSIN |
| Strength(s) | 20UNIT | 20UNIT |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR |
| Packaging size | 1 mL | 1 mL |
| Additional packaging sizes | ||
| ATC code | H01BA | H01BA |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2026-02-01 | 2026-02-01 |
| Actual start date | ||
| Estimated end date | 2026-03-31 | 2026-03-31 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Due to production delays, allocations for our Vasopressin Injection, USP 20 USP units/mL, 1 mL Vial, will be reduced effective February 1, 2026. Customers will be allocated 50% of historical monthly demand. Effective March 1, 2026, until March 31, 2026, we will encounter a backorder on this product. | Due to production delays, allocations for our Vasopressin Injection, USP 20 USP units/mL, 1 mL Vial, will be reduced effective February 1, 2026. Customers will be allocated 50% of historical monthly demand. Effective March 1, 2026, until March 31, 2026, we will encounter a backorder on this product. |
| Health Canada comments |